JP6929230B2 - スペーサーを含む核酸分子およびその使用の方法 - Google Patents

スペーサーを含む核酸分子およびその使用の方法 Download PDF

Info

Publication number
JP6929230B2
JP6929230B2 JP2017559315A JP2017559315A JP6929230B2 JP 6929230 B2 JP6929230 B2 JP 6929230B2 JP 2017559315 A JP2017559315 A JP 2017559315A JP 2017559315 A JP2017559315 A JP 2017559315A JP 6929230 B2 JP6929230 B2 JP 6929230B2
Authority
JP
Japan
Prior art keywords
nucleic acid
length
spacer
vector
itr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017559315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018515102A (ja
JP2018515102A5 (cg-RX-API-DMAC10.html
Inventor
グレイ，ジョン，ティー．
Original Assignee
セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド, セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド filed Critical セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
Publication of JP2018515102A publication Critical patent/JP2018515102A/ja
Publication of JP2018515102A5 publication Critical patent/JP2018515102A5/ja
Priority to JP2021130440A priority Critical patent/JP7316326B2/ja
Application granted granted Critical
Publication of JP6929230B2 publication Critical patent/JP6929230B2/ja
Priority to JP2023115773A priority patent/JP7796702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8616—Special methods for targeting systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Manufacturing & Machinery (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017559315A 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法 Active JP6929230B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021130440A JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法
JP2023115773A JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562161505P 2015-05-14 2015-05-14
US62/161,505 2015-05-14
PCT/US2016/032321 WO2016183422A1 (en) 2015-05-14 2016-05-13 Nucleic acid molecules containing spacers and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021130440A Division JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2018515102A JP2018515102A (ja) 2018-06-14
JP2018515102A5 JP2018515102A5 (cg-RX-API-DMAC10.html) 2019-06-13
JP6929230B2 true JP6929230B2 (ja) 2021-09-01

Family

ID=57249066

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017559315A Active JP6929230B2 (ja) 2015-05-14 2016-05-13 スペーサーを含む核酸分子およびその使用の方法
JP2021130440A Active JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法
JP2023115773A Active JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021130440A Active JP7316326B2 (ja) 2015-05-14 2021-08-10 スペーサーを含む核酸分子およびその使用の方法
JP2023115773A Active JP7796702B2 (ja) 2015-05-14 2023-07-14 スペーサーを含む核酸分子およびその使用の方法

Country Status (5)

Country Link
US (2) US11103597B2 (cg-RX-API-DMAC10.html)
EP (1) EP3294309A4 (cg-RX-API-DMAC10.html)
JP (3) JP6929230B2 (cg-RX-API-DMAC10.html)
AU (3) AU2016260401B2 (cg-RX-API-DMAC10.html)
WO (1) WO2016183422A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof
WO2017066579A1 (en) 2015-10-14 2017-04-20 Audentes Therapeutics, Inc. Nucleic acid molecules containing spacers and methods of use thereof
EP3609524A4 (en) * 2017-04-14 2021-01-27 Rhode Island Hospital VEGF GENE USED FOR THE TREATMENT OF TENDON OR LIGAMENT DAMAGE
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
MX2020009579A (es) * 2018-03-15 2020-11-09 Intergalactic Therapeutics Inc Vectores de adn sintetico y metodos de uso.
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
EP3870148A4 (en) 2018-10-25 2022-11-09 Takeda Pharmaceutical Company Limited AAV TRIPLE PLASMID SYSTEM
WO2021055760A1 (en) 2019-09-18 2021-03-25 Intergalactic Therapeutics, Inc. Synthetic dna vectors and methods of use
CN115197967B (zh) * 2021-04-08 2023-09-15 广州派真生物技术有限公司 制备重组腺相关病毒的辅助质粒及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
WO1998010086A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Methods using cre-lox for production of recombinant adeno-associated viruses
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU3642601A (en) 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
US20020182595A1 (en) 2001-04-27 2002-12-05 Weitzman Matthew D. Method of identifying cellular regulators of adeno-associated virus (AAV)
US8067156B2 (en) 2001-05-31 2011-11-29 The Rockefeller University Method for generating replication defective viral vectors that are helper free
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
AU2003278882A1 (en) 2002-09-26 2004-04-19 Greenville Hospital System Aav itr-mediated modulation
ES2436741T3 (es) * 2004-09-22 2014-01-07 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US9169494B2 (en) 2010-01-12 2015-10-27 The University Of North Carolina At Chapel Hill Restrictive inverted terminal repeats for viral vectors
US9249425B2 (en) * 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US9124527B2 (en) * 2012-08-29 2015-09-01 International Business Machines Corporation Sliced routing table management
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
JP2016517278A (ja) * 2013-03-15 2016-06-16 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ スタッファー／フィラーポリヌクレオチド配列を含むベクターおよびその使用方法
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
NZ716102A (en) * 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
SG11201701033QA (en) * 2014-08-13 2017-03-30 Philadelphia Children Hospital An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders
AU2016260401B2 (en) 2015-05-14 2022-05-19 St. Jude Children's Research Hospital, Inc. Nucleic acid molecules containing spacers and methods of use thereof

Also Published As

Publication number Publication date
AU2016260401B2 (en) 2022-05-19
JP2018515102A (ja) 2018-06-14
AU2022215274A1 (en) 2022-09-01
JP7316326B2 (ja) 2023-07-27
WO2016183422A1 (en) 2016-11-17
CA2983593A1 (en) 2016-11-17
EP3294309A1 (en) 2018-03-21
JP7796702B2 (ja) 2026-01-09
JP2021184734A (ja) 2021-12-09
US12453783B2 (en) 2025-10-28
US20180126006A1 (en) 2018-05-10
US11103597B2 (en) 2021-08-31
JP2023138527A (ja) 2023-10-02
AU2025203194A1 (en) 2025-05-22
US20210369869A1 (en) 2021-12-02
AU2016260401A1 (en) 2017-11-02
EP3294309A4 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
JP7796702B2 (ja) スペーサーを含む核酸分子およびその使用の方法
JP7561788B2 (ja) 臨床使用に適した無血清懸濁細胞培養システムにおいて組換えアデノ随伴ウイルス（ａａｖ）ベクターを産生するスケーラブルな方法
KR102526711B1 (ko) 고효율 게놈 편집을 위한 아데노-관련 바이러스 벡터 변이체 및 이의 방법
US7037713B2 (en) High-efficiency wild-type-free AAV helper functions
CN102212558B (zh) 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
EP3870148A1 (en) Aav triple-plasmid system
US12600986B2 (en) Nucleic acid molecules containing spacers and methods of use thereof
WO2018200419A1 (en) Viral vectors comprising engineered aav capsids and compositions containing the same
WO2017181162A1 (en) Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
AU2021215885A1 (en) DNA amplification method
WO2020218419A1 (ja) 脳に指向性を有するａａｖ変異体
US20020177222A1 (en) Replication competent AAV helper functions
WO2024050547A2 (en) Compact bidirectional promoters for gene expression
CN120818522B (zh) 一种基于itr-增强子驱动核酸表达的调控元件组合及其应用
Smith et al. Transposase-mediated construction of an integrated adeno-associated virus type 5 helper plasmid
CA2983593C (en) Nucleic acid molecules containing spacers and methods of use thereof
JP2023029866A (ja) パルボウイルスベクターの産生
WO2025023319A1 (ja) 脳指向性ａａｖ変異体
WO2026020116A1 (en) Methods and compositions for enriching the production of dna cargo loaded recombinant adeno-associated virus capsids
HK40128602A (en) Improved recombinant polyadenylation signal sequences and use thereof
CN114736928A (zh) 一种杆状病毒载体及其在昆虫细胞中制备rAAV的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210810

R150 Certificate of patent or registration of utility model

Ref document number: 6929230

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250